15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Nektar Therapeutics, 7 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $80.00 to $192.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $151.00 sits 113% above the current $70.78. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.52 next quarter toward $-11.87 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Strong Buy
Strong Buy00%
Buy788%
Hold113%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Nektar Therapeutics.
As of Jul, 7 of 8 firms rate NKTR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NKTR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.52
Range $-3.15 – $5.30 · 4 analysts · -72% YoY
Next period, 4 analysts expect Nektar Therapeutics to earn $-0.52 a share (range $-3.15 – $5.30), versus $-1.87 a year earlier. Full-year consensus is $-9.54, growing to $-11.87 the year after.
REVENUE · NEXT QUARTER
$10.3M
Range $6.0M – $11.3M · 4 analysts · -13% YoY
Revenue is expected to reach $10.3M (range $6.0M – $11.3M), -13.0% year-over-year. Full-year consensus is $41.4M, rising to $37.0M next year.
Top analysts covering Nektar Therapeutics
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NKTR.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$150.00+111.9% to target
Overall win rate
53%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #64
Sell
$30.00-57.6% to target
Overall win rate
52%
+ Follow
#3
Arthur He
HC Wainwright & Co. · Rank #150
Buy
$185.00+161.4% to target
Overall win rate
48%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$192.00+171.3% to target
Overall win rate
34%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #302
Buy
$140.00+97.8% to target
Overall win rate
32%
+ Follow
NKTR stock forecast FAQ
What is NKTR's average 12-month price target?+
The 7 analysts with a live target average $151.00 for Nektar Therapeutics over the next 12 months, ranging from a $192.00 high to a $80.00 low.
Is NKTR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 8 analyst ratings, 7 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NKTR?+
The Street-high target is $192.00 (Piper Sandler), and the Street-low is $80.00 (Wedbush). The average of all 7 active targets is $151.00.
How many Wall Street analysts cover NKTR?+
8 analysts have an active rating on Nektar Therapeutics, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering NKTR?+
Among analysts who currently cover NKTR, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $150.00 target.
What is Nektar Therapeutics's projected EPS for next quarter?+
The consensus estimate is $-0.52 per share (range $-3.15 – $5.30) across 4 analysts. Full-year EPS is projected at $-9.54, rising to $-11.87 the following year.
How much revenue is Nektar Therapeutics expected to report next quarter?+
Consensus revenue is $10.3M (range $6.0M – $11.3M). Full-year revenue is projected at $41.4M, growing to $37.0M next year.
Have analysts been upgrading or downgrading NKTR lately?+
As of Jul, 7 of 8 firms rate NKTR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NKTR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
